Value2020202120222023TTMSelling/general/admin expenses775.03 M600.51 M687.44 M591.41 M599.31 MResearch & development483.04 M525.22 M501.74 M550.41 M628.11 M영업 이익-1.35 B-1.18 B4.24 B-1 B-1.22 BNon-Operating Income, Total-90.73 M24.27 M-21.29 M47.57 M265.4 MInterest expense, net of interest capitalized7.04 M27.97 M34.78 M——Non-Operating Income, excl. Interest Expenses-94.33 M-19.51 M-49.98 M58.29 M276.8 MUnusual income/expense-3.44 M15.81 M-6.09 M-10.72 M-11.4 MPretax income-923.75 M-1.22 B4.25 B-681.59 M-921.73 MEquity in earnings0————Taxes369 K5.19 M22.22 M48.17 M84.3 MNon-controlling/minority interest-78.85 M-106.43 M-117.72 M-184.75 M-196.79 MAfter tax other income/expense-13.82 M21.21 M-10.25 M-3.76 M-11.57 MNet income before discontinued operations-845.26 M-1.12 B4.35 B-545.01 M-809.24 MDiscontinued operations—114.56 M0373.03 M0Net income-845.26 M-1.01 B4.35 B-171.98 M-809.24 MDilution adjustment—————Preferred dividends—————Diluted net income available to common stockholders-845.26 M-1.01 B4.35 B-171.98 M-809.24 MBasic earnings per share (Basic EPS)—-1.425.55-0.24-1.17Diluted earnings per share (Diluted EPS)—-1.425.23-0.24-1.16Average basic shares outstanding—712.79 M783.25 M725.4 M2.78 BDiluted shares outstanding—712.79 M831.05 M725.4 M2.78 BEBITDA—-1.16 B-1.08 B-1.1 B-1.21 BEBIT-1.35 B-1.18 B-1.11 B-1.11 B-1.22 BCost of revenue—————Other cost of goods sold—————Depreciation & amortization (cash flow)—18.86 M22.04 M14.07 M4.13 M
Roivant Sciences Ltd
Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. It was founded in 2014 by Vivek Ramaswamy and is currently headed by CEO Matt Gline. Roivant maintains its headquarters in New York City as well as major offices in the biotech hubs of Boston and Basel.